

ALTANA AG
Postfach 10 12 15, 46472 Wesel, Germany

H1/Q2 2007 Reporting — Comparable basis H1/Q2 2006

Dear Madam or Sir,

Until the end of the business year 2006, the ALTANA Group consisted of the two divisions ALTANA Chemie and ALTANA Pharma as well as the ALTANA AG holding company. ALTANA Pharma was sold effective December 31, 2006. As a consequence, reported figures for the year 2006 will be adjusted to reflect the continuing operations (ALTANA Chemie and ALTANA AG holding).

In preparation for the reporting of H1/Q2 2007 results on August 8, 2007 we herewith would like to provide you with the corresponding comparable basis for H1/Q2 2006.

H1/Q2 2006 – CONTINUING OPERATIONS:

(in Mio. €)	H1/2006	Q2/2006
Sales	659.0	334.5
Earnings before interest, taxes, depreciation and amortization (EBITDA)	103.1	53.1
EBITDA margin	15.6%	15.8%
Earnings before interest and taxes (EBIT)	64.4	34.1
EBIT margin	9.8%	10.2%
Earnings before taxes (EBT)	62.7	33.6
EBT margin	9.5%	10.1%
Net income (EAT)	39.8	21.3
EAT margin	6.0%	6.4%
Earnings per share (EPS), €	0.29	0.15
R&D expenditure	33.5	16.9
Capital expenditure	31.5	17.0

Date
July 26, 2007

Page
1/2

Your contact
Corporate Communications
Achim Struchholz

Tel (direct)
+49 281 670-2460

Fax (direct)
+49 281 670-1114

E-mail
press@altana.com

ALTANA AG
Abelstrasse 45
46483 Wesel
Germany
Tel +49 281 670-8
Fax +49 281 65735
info@altana.com
www.altana.com

Chairman of the
Supervisory Board
Dr. Fritz Fröhlich

Management Board
Dr. Matthias L. Wolfgruber (CEO)
Martin Babilas (CFO)

Bank
Commerzbank AG, Wesel
Account-No. 1 330 299
BLZ 356 400 64

Registered
Registered Office: Wesel
Registry Court: Duisburg
HRB-No. 19496

In case of any questions, please do not hesitate to contact us.

With best regards

Achim Struchholz
Head of Corporate Communications

Tel (direct): +49 281 670-2460
E-mail: press@altana.com